Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Amanda Pilling"'
Autor:
Amanda Pilling, Christopher Wee, Eliezer Bar-Meir, Gregory Dyson, Ok Hwang, Nilesh Gupta, Dhananjay Chitale, Clara Hwang
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 2, Pp 1194-1200 (2021)
Through elucidating the genetic mechanisms of drug sensitivity, precision medicine aims to improve patient selection and response to therapy. Exceptional responders are patients that exhibit exquisite and durable responses to targeted therapy, provid
Externí odkaz:
https://doaj.org/article/76027a3d81af444f87eb9583bc44d535
Publikováno v:
The Prostate. 83:524-533
Inactivating alterations in SPOP frequently occur in prostate cancer and promote increased dependency on androgen receptor (AR)-mediated oncogenic signaling. The presence of SPOP mutation (SPOP-mutant [SPOP-mut]) may therefore impact therapeutic outc
Autor:
Christopher Wee, Nilesh S. Gupta, Dhananjay Chitale, Ok Hwang, Gregory Dyson, Clara Hwang, Amanda Pilling, Eliezer Bar-Meir
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 2, Pp 1194-1200 (2021)
Case Reports in Oncology
Case Reports in Oncology
Through elucidating the genetic mechanisms of drug sensitivity, precision medicine aims to improve patient selection and response to therapy. Exceptional responders are patients that exhibit exquisite and durable responses to targeted therapy, provid
Publikováno v:
The Prostate. 82(2)
BACKGROUND Despite multiple treatment advances for castration-resistant prostate cancer (CRPC), there are currently no curative therapies and patients ultimately to succumb to the disease. Docetaxel (DTX) is the standard first-line chemotherapy for p
Autor:
Amanda Pilling, Clara Hwang
Publikováno v:
The Prostate
Background Prostate cancer that recurs after initial treatment inevitably progresses to castration‐resistant prostate cancer (CRPC), the lethal stage of the disease. Despite improvements in outcomes from next generation androgen receptor (AR)‐axi
Publikováno v:
Journal of Clinical Oncology. 40:e21015-e21015
e21015 Background: African American (AA) individuals are disproportionately affected by lung cancer in terms of incidence and mortality, despite lower tobacco exposure compared to Caucasian Americans (CA). Since molecular profiling is critically impo
Autor:
Clara Hwang, Nicholas Henderson, Frank Cameron Cackowski, Amanda Pilling, Albert Jang, Shoshana Rothstein, Matthew Labriola, Joseph J. Park, Alyssa Ghose, Mehmet Asim Bilen, Deepak Kilari, Abhishek Tripathi, Rohan Garje, Vadim S Koshkin, Michael Thomas Schweizer, Andrew J. Armstrong, Rana R. McKay, Tanya B. Dorff, Ajjai Shivaram Alva, Pedro C. Barata
Publikováno v:
Journal of Clinical Oncology. 40:5013-5013
5013 Background: Black men have been underrepresented in large-scale molecular prostate cancer (PC) surveys, despite having higher PC incidence and mortality. Since molecular profiling to guide the use of targeted agents is increasingly important in
Autor:
Alicia Ali, Scott T. Tagawa, Frank C. Cackowski, Vaibhav G. Patel, Divya Natesan, Clara Hwang, Michael Pierro, Ajjai Alva, Joseph J. Park, Tanya B. Dorff, Bicky Thapa, Susan Halabi, Colin Pritchard, Michael T. Schweizer, Rohan Garje, Abhishek Tripathi, Rana R. McKay, Albert Jang, Marcin Cieslik, Catherine Handy Marshall, Laura S Graham, Justin Shaya, Tomi Jun, Landon Carter Brown, Alleda Mack, Elisabeth I. Heath, Vadim S. Koshkin, Christopher Nguyen, Pedro C. Barata, Olesia Kellezi, Deepak Kilari, Mehmet Asim Bilen, Sanober Nusrat, Luna Acharya, Deepak Ravindranathan, Matthew Labriola, Andrew J. Armstrong, William Oh, Shuang R. Chen, Angelo Cabal, Amanda Pilling
Publikováno v:
Prostate cancer and prostatic diseases. 25(3)
Purpose Prostate cancer is a heterogeneous disease with variable clinical outcomes. Despite numerous recent approvals of novel therapies, castration-resistant prostate cancer remains lethal. A “real-world” clinical-genomic database is urgently ne
Publikováno v:
The Prostate. 77:866-877
Background Castration-resistant prostate cancer (CRPC) remains incurable and identifying effective treatments continues to present a clinical challenge. Although treatment with enzalutamide, a second generation androgen receptor (AR) antagonist, prol
Autor:
Amanda Pilling, Lucas Maahs, Clara Hwang, Andrew Stangl, Charlotte Burmeister, Christopher Willner
Publikováno v:
Journal of Clinical Oncology. 39:160-160
160 Background: Predictive markers linking molecular background to treatment response and clinical outcomes are currently lacking in prostate cancer. Missense mutations in SPOP (speckle-type POZ protein) define a distinct molecular subtype, occurring